Forte Biosciences

News

Netherlands- and Belgium-based argenx has agreed to buy US biotech Forte Bio for up to $2.2bn, bolstering its autoimmune disease pipeline.

News

Ultragenyx secured its first gene therapy approval, the FDA clearing GENGLYCOS as the first treatment designed to address underlying cause of GSDla.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.